Title |
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
|
---|---|
Published in |
BMC Cancer, September 2012
|
DOI | 10.1186/1471-2407-12-438 |
Pubmed ID | |
Authors |
Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños, Claus-Henning Köhne |
Abstract |
Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
Netherlands | 1 | 1% |
Unknown | 68 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 17% |
Other | 9 | 13% |
Student > Bachelor | 8 | 11% |
Student > Master | 5 | 7% |
Student > Doctoral Student | 3 | 4% |
Other | 12 | 17% |
Unknown | 21 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 37% |
Agricultural and Biological Sciences | 6 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 4% |
Nursing and Health Professions | 3 | 4% |
Social Sciences | 2 | 3% |
Other | 7 | 10% |
Unknown | 23 | 33% |